Look into the Bright Future of Rare Cancer Research!
Rare oncology research is advancing fast as science expands its understanding of cancer’s genetic and molecular origins. In 2014, more than four in 10 new orphan drug designations went to treatments for rare cancers — clear evidence that the implications of this work reach far beyond the laboratory.
Premier Research looks at trends and issues in a new white paper, Rapid Change, Real Promise: The Future of Rare Oncology Research. Available now for download, it offers insights into major issues in rare cancer research, including:
- What do patients want? For starters, innovation, more options, and input into the clinical process.
- Innovative trial designs: adaptive design, basket trials, umbrella trials, and other alternative approaches.
- Regulation: how the FDA and EMA are facilitating expedited review of drugs that target unmet medical needs.
- Pending legislation that may affect how future studies are performed.
And there’s more: working with sparse data, overcoming limited treatment options, and the growing role of patient advocacy groups. Get the full story today!
We’re excited to sponsor this week’s World Orphan Drug Congress, and can’t wait to see you there!